Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and meta …

C Huang - Journal of Medical Virology, 2023 - search.ebscohost.com
The study by Arribas et al. included 99 (43.8%) severe COVID-19 patients in the
molnupiravir therapy group, with 175 (77.4%) patients experiencing a delay of more than 5 …
相关文章

[引用][C] Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and …

C Huang - Journal of Medical Virology, 2023 - europepmc.org
A comment on this article appears in" Response to the letter to the editor on" Clinical efficacy
and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A …

[引用][C] Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and …

C Huang - Journal of Medical Virology, 2023 - Wiley Online Library
Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized
and hospitalized patients with COVID‐19: A systematic review and meta‐analysis of …